1. In Vivo
  2. >>Archive

BD's Progress in Molecular Markers

Having already collaborated with Millennium Pharmaceuticals to find marker candidates for its molecular oncology program, BD is now tapping TriPath Imaging to help build an imaging system to analyze the markers. Its strategy of relying on partners means it has to give up some profits, but BD is confident that the results will yield a value high enough to make the program economically feasible. It's a model that other companies are likely to emulate as they move into molecular diagnostics.

More than two years ago, Becton Dickinson & Co. became the first company to sign a big-stakes diagnostics deal with Millennium Pharmaceuticals Inc. , investing unprecedented amounts of money in exchange for Millennium's yet-unproven expertise in finding high-value, patentable genomic markers for oncology. The agreement was noteworthy not only because of the amount of money involved—more than $70 million if it worked out—but because it exemplified a new paradigm for discovering new tests, the kind of strategy that had the potential to lead the diagnostics industry out of its slow-growth, low-margin cycle [See Deal]. (See "Becton Dickinson's Magic Markers," IN VIVO, May 1999 [A#1999800719].)

Now, in an indication of progress, BD has signed a strategic alliance with TriPath Imaging Inc. , to help...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.